Allergic Contact Dermatitis Clinical Trial
Official title:
Oral Human Administration of Red Grape Polyphenol in Nickel-mediated Allergic Contact Dermatitis: an in Vitro Study
Nickel (Ni)-mediated allergic contact dermatitis (ACD) is a very common disease worldwide. Our previous findings demonstrated that in vitro supplementation of polyphenols, extracted from seeds of red grape (Nero di Troia cultivar), to peripheral lymphomonocytes from Ni-mediated ACD patients could reduce release of T helper (h)1 [interferon (IFN)-] and Th2 [interleukin (IL)-4] cytokines, on the one hand. On the other hand, IL-10 (an anti-inflammatory cytokine) levels increased with a reduction of IL-17 (an inflammatory cytokine). Also levels of nitric oxide (NO) decreased in response to polyphenol pretreatment.
Nickel (Ni) is a transitional metal largely distributed in the environment whose continuous exposure is able to provoke local and systemic allergic contact dermatitis (ACD). Ni-mediated ACD is characterized by loss of epidermal integrity, urticaria/angioedema, flares, and itching, whose extent depends on many variables such as genetic, time of sensitization and environmental exposure.The aim of the present research is to verify whether the oral administration of polyphenols (NATUR-OX®) to patients with Ni-mediated ACD is able to modify immune parameters. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03945760 -
Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects
|
Early Phase 1 | |
Not yet recruiting |
NCT05498467 -
The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis
|
Phase 3 | |
Active, not recruiting |
NCT03680131 -
Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis
|
Phase 2 | |
Recruiting |
NCT05535738 -
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation
|
Phase 2/Phase 3 | |
Recruiting |
NCT06191627 -
Patient Experience and Quality of Patch Testing on the Legs vs Back
|
N/A | |
Completed |
NCT00867607 -
Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis
|
Phase 1/Phase 2 | |
Recruiting |
NCT00445029 -
Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation
|
N/A | |
Completed |
NCT04365140 -
MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel
|
||
Recruiting |
NCT05991674 -
A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning Techniques
|
||
Completed |
NCT00931242 -
Study of Apremilast in Atopic or Contact Dermatitis
|
Phase 2 | |
Completed |
NCT01798589 -
Bioequivalence of Ethylenediamine Dihydrochloride Study
|
Phase 4 | |
Completed |
NCT01546298 -
Immune Reactions in Contact Dermatitis Affected Skin
|
||
Completed |
NCT05339750 -
Allergy Skin Patch Artificial Intelligence (AI)
|
N/A | |
Recruiting |
NCT03935971 -
The Effects of Dupilumab on Allergic Contact Dermatitis
|
Phase 4 | |
Completed |
NCT01797562 -
Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents
|
N/A | |
Not yet recruiting |
NCT05858723 -
Repeated Open Application Test (ROAT) Study With Hydroperoxides of Linalool
|
N/A | |
Completed |
NCT02534441 -
Epidemiology and Co-Reactivity of Novel Surfactant Allergens
|
N/A | |
Not yet recruiting |
NCT01413477 -
Nickel Desensitization Using Topical Therapy
|
N/A | |
Completed |
NCT00132600 -
Clinical Evaluation of Bacitracin
|
Phase 2 | |
Completed |
NCT00133341 -
Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate
|
Phase 2 |